Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors
- 1 March 2002
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 27 (1) , 61-65
- https://doi.org/10.1007/bf03190407
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced CancerJournal of Clinical Oncology, 2002
- Farnesyl transferase inhibitors: current developments and future perspectivesCancer Treatment Reviews, 2000
- Clinical evaluation of biologically targeted drugs: obstacles and opportunities.Cancer Chemotherapy and Pharmacology, 1998
- A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.1995
- Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.Proceedings of the National Academy of Sciences, 1994
- Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeuticCell, 1994
- ras and human tumors.1992
- GTPase activating proteins.1992
- ras GENESAnnual Review of Biochemistry, 1987
- Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virusNature, 1980